Literature DB >> 17044583

Management of sepsis during the early "golden hours".

Murugan Raghavan1, Paul E Marik.   

Abstract

Severe sepsis and septic shock are common causes of morbidity and mortality. Interventions directed at specific endpoints, when initiated early in the "golden hours" of patient arrival at the hospital, seem to be promising. Early hemodynamic optimization, administration of appropriate antimicrobial therapy, and effective source control of infection are the cornerstones of successful management. In patients with vasopressor-dependent septic shock, provision of physiologic doses of replacement steroids may result in improved survival. Administration of drotrecogin alfa (activated), (activated protein C) has been shown to improve survival in patients with severe sepsis and septic shock who have a high risk of mortality. In this article we review the multi-modality approach to early diagnosis and intervention in the therapy of patients with severe sepsis and septic shock.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17044583     DOI: 10.1016/j.jemermed.2006.05.008

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  19 in total

1.  Sepsis and its consequences.

Authors:  Kevin M Ban; Peter Rosen
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

2.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

3.  An evaluation of clinical order patterns machine-learned from clinician cohorts stratified by patient mortality outcomes.

Authors:  Jason K Wang; Jason Hom; Santhosh Balasubramanian; Alejandro Schuler; Nigam H Shah; Mary K Goldstein; Michael T M Baiocchi; Jonathan H Chen
Journal:  J Biomed Inform       Date:  2018-09-07       Impact factor: 6.317

4.  Evaluation of the modified MEDS, MEWS score and Charlson comorbidity index in patients with community acquired sepsis in the emergency department.

Authors:  Ergün Çıldır; Mehtap Bulut; Halis Akalın; Egemen Kocabaş; Gökhan Ocakoğlu; Şule Akköse Aydın
Journal:  Intern Emerg Med       Date:  2012-12-19       Impact factor: 3.397

5.  Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial.

Authors:  Amos Lal; Vrinda Trivedi; Mahrukh S Rizvi; Amy Amsbaugh; Melissa K Myers; Khaled Saleh; Rahul Kashyap; Ognjen Gajic
Journal:  Crit Care Explor       Date:  2021-05-06

6.  Evaluation of prognostic value of selected biochemical markers in surgically treated patients with acute mediastinitis.

Authors:  Sławomir Jabłoński; Marian Brocki; Kujawski Krzysztof; Marcin Wawrzycki; Edyta Santorek-Strumiłło; Marek Łobos; Marcin Kozakiewicz
Journal:  Med Sci Monit       Date:  2012-05

7.  Surviving sepsis: going beyond the guidelines.

Authors:  Paul E Marik
Journal:  Ann Intensive Care       Date:  2011-06-07       Impact factor: 6.925

8.  A method to determine spatial access to specialized palliative care services using GIS.

Authors:  Jonathan Cinnamon; Nadine Schuurman; Valorie A Crooks
Journal:  BMC Health Serv Res       Date:  2008-06-30       Impact factor: 2.655

9.  Differences in compliance with Surviving Sepsis Campaign recommendations according to hospital entrance time: day versus night.

Authors:  Mónica Almeida; Orquídea Ribeiro; Irene Aragão; Altamiro Costa-Pereira; Teresa Cardoso
Journal:  Crit Care       Date:  2013-04-23       Impact factor: 9.097

10.  Impact of positive fluid balance on mortality and length of stay in septic shock patients.

Authors:  Wachiraporn Koonrangsesomboon; Bodin Khwannimit
Journal:  Indian J Crit Care Med       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.